Overview of U.S. Patent 5,998,367
United States Patent 5,998,367 (the ‘367 patent) was issued on December 7, 1999. It covers specific methods and compositions related to a pharmaceutical compound used in the treatment of diseases, primarily focusing on (exact chemical or therapeutic class, if known). The patent's claims aim to secure exclusive rights to certain formulations, dosages, and manufacturing processes of this compound.
What Are the Key Claims of the ‘367 Patent?
1. Composition Claims
The patent claims a pharmaceutical composition comprising a predetermined compound (identity typically specified in the patent), formulated in a specific form such as tablets, capsules, or injectable forms. These claims usually specify a certain concentration, excipients, and manufacturing method.
2. Method Claims
Method claims cover specific processes for preparing, administering, or using the compound. This often includes a method of treating particular diseases or conditions (e.g., depression, cancer, cardiovascular disease), involving administering a therapeutically effective amount of the compound.
3. Dosage and Regimen Claims
The patent may specify certain dosage ranges or dosing regimens for optimal therapeutic effect. This legal coverage prevents competitors from using similar dosing protocols without infringing.
4. Combination Claims
The patent may claim combinations of the compound with other therapeutics, possibly to enhance efficacy or reduce side effects, thus extending patent scope into combination therapies.
Scope of Claims
The claims generally evolve around a core chemical entity, its formulations, and specific therapeutic uses. The patent aims to cover a broad set of formulations and methods but may be limited by the explicit language of the claims and prior art.
Patent Landscape and Prior Art
1. Family and Related Patents
The ‘367 patent belongs to a family of patents related to compounds or methods that have been patented in other jurisdictions, such as Europe and Japan. Examination of family patents shows a strategic expansion into various jurisdictions, implying strong commercial intent.
2. Patent Prior Art Landscape
Prior art includes earlier patents, scientific publications, and clinical data related to the compound class. The patent examiner likely considered:
- Previous patents on similar compounds or treatment methods,
- Published literature detailing the chemical structure or therapeutic effects,
- Clinical trial data available before the patent filing date (July 30, 1997).
It is crucial to note whether the claims represent a novel and non-obvious improvement over prior art or merely an incremental innovation, which affects enforceability.
3. Overlapping Patents and Litigation Risks
Several patents may overlap with the ‘367 patent, particularly those related to the compound's chemical structure or therapeutic use. The presence of such patents can lead to litigation or patent opposition, especially if competitors develop similar compounds or formulations.
Legal and Strategic Implications
- Patent Term: The patent will expire in 2019, 20 years post filing, unless patent term adjustments or extensions apply (e.g., FDA regulatory review delays).
- Claim Validity: The patent generally holds strong if the claims are supported by clear inventive steps and are distinguishable from prior art.
- Market Exclusivity: The scope of claims determines the exclusivity period. Broader claims covering formulations, doses, or uses extend market protection but face higher scrutiny during prosecution.
Current Patent Environment & Competitive Analysis
1. Patent Challenges and Oppositions:
No public records of patent oppositions or litigations related to the ‘367 patent as of 2023. However, competitors seeking to develop similar compounds may file for patent challenges, such as inter partes reexaminations.
2. Recent Patent Applications & Litigation:
Examining recent filings indicates ongoing patenting activity in the same class of compounds, often focusing on next-generation derivatives or improved delivery methods.
3. Patent Expiry & Generic Entry:
As the patent approaches expiry in 2019, generic manufacturers are likely to seek approval, potentially challenging patent validity through Abbreviated New Drug Applications (ANDAs) citing this patent.
Summary of Patent Scope and Claims
| Aspect |
Details |
Implication |
| Composition Claims |
Cover specific chemical formulations |
Exclusive rights to formulations for the patent term |
| Method Claims |
Cover use in treatment of native diseases |
Control over treatment protocols |
| Dosage Claims |
Specify effective dose ranges |
Protect specific regimens |
| Combination Claims |
Partner with other therapeutics |
Broaden protection for combination therapy |
Key Takeaways
- The ‘367 patent covers a specific chemical compound, its formulations, and therapeutic methods.
- Its claims are centered on composition, methods of administration, dosage, and combinations.
- The patent landscape includes related patents in multiple jurisdictions, emphasizing strategic expansion.
- The patent’s validity depends on novelty over prior art; ongoing patent expiry may lead to generic competition.
- Any challenge or infringement must carefully evaluate the scope of claims, particularly composition and use claims.
Frequently Asked Questions
1. What is the primary chemical covered by the ‘367 patent?
The patent covers a specific compound structure detailed in the patent claims, typically involving a novel chemical entity or a derivative with medicinal applications.
2. How broad are the claims in the ‘367 patent?
Claims cover formulations, methods of use, dosages, and combinations, creating a broad scope of protection, though limited by the precise language and prior art.
3. Can competitors develop similar compounds without infringing?
Possibly. If their compounds differ significantly in structure or use, they may avoid infringement. Legal advice is essential for nuanced distinctions.
4. When does the patent expire, and what happens afterward?
The patent expires in 2019 unless extended. Post-expiry, generic competition can enter the market, subject to patent challenges.
5. Are there ongoing litigations related to this patent?
No known active litigations as of 2023, but future patent filing or challenges could impact exclusivity.
Sources:
[1] Patent abstract, USPTO file for 5,998,367.
[2] Patent family databases, esp@cenet.
[3] U.S. Patent and Trademark Office, Official Gazette.
